Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Katherine A. Eade Insider Profile
4 Followers
Katherine A. Eade, Director at Harvard Bioscience, holds 311.13K shares in Harvard Bioscience (Ticker: HBIO), holds ― shares in Vaxxinity Inc (Ticker: VAXX).
Katherine A. Eade has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Katherine A. Eade holds in companies
Most Profitable Insider Trade
The most profitable trade made by Katherine A. Eade
Katherine A. Eade's Trading History
Harvard Bioscience
May 23, 2024
Director
Uninformative Buy
―
$746.70K
Vaxxinity Inc
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Katherine A. Eade's performance on stock
You May Also Like
Katherine A. Eade insider profile FAQ
What is the percentage of profitable transactions made by Katherine A. Eade?
The percentage of profitable transactions made by Katherine A. Eade is ―.
What is the average return per transaction made by Katherine A. Eade?
The average return per transaction made by Katherine A. Eade is ―.
What stocks does Katherine A. Eade hold?
Katherine A. Eade holds: HBIO, VAXX stocks.
What was Katherine A. Eade’s latest transaction?
Katherine A. Eade latest transaction was an Uninformative Buy of ―.
What was Katherine A. Eade's most profitable transaction?
Katherine A. Eade’s most profitable transaction was an Informative Buy of HBIO stock on August 12, 2019. The return on the trade was 48.80%.
What is Katherine A. Eade's role in Harvard Bioscience?
Katherine A. Eade's role in Harvard Bioscience is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.